Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017094705) GM3-PROMOTED INFLAMMATION INHIBITOR AND INFLAMMATORY CYTOKINE PRODUCTION INHIBITOR
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/094705 International Application No.: PCT/JP2016/085323
Publication Date: 08.06.2017 International Filing Date: 29.11.2016
IPC:
A61K 45/00 (2006.01) ,A61K 31/739 (2006.01) ,A61P 29/00 (2006.01) ,A61P 37/06 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof
715
Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
739
Lipopolysaccharides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29
Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37
Drugs for immunological or allergic disorders
02
Immunomodulators
06
Immunosuppressants, e.g. drugs for graft rejection
Applicants:
公益財団法人野口研究所 THE NOGUCHI INSTITUTE [JP/JP]; 東京都板橋区加賀一丁目9番7号 1-9-7, Kaga, Itabashi-ku, Tokyo 1730003, JP
Inventors:
井ノ口 仁一 INOKUCHI Jin-ichi; JP
狩野 裕考 KANOH Hirotaka; JP
ソニーノ サンドロ SONNINO Sandro; IT
Agent:
特許業務法人たかはし国際特許事務所 TAKAHASHI INTERNATIONAL PATENT OFFICE; 東京都杉並区上荻一丁目25番1号 ヤマキ産業ビル2階 YAMAKISANGYO Bldg. 2F, 25-1, Kamiogi 1-chome, Suginami-ku, Tokyo 1670043, JP
Priority Data:
2015-23256430.11.2015JP
2016-11418808.06.2016JP
Title (EN) GM3-PROMOTED INFLAMMATION INHIBITOR AND INFLAMMATORY CYTOKINE PRODUCTION INHIBITOR
(FR) INHIBITEUR D'INFLAMMATION STIMULÉE PAR GM3 ET INHIBITEUR DE PRODUCTION DE CYTOKINES INFLAMMATOIRES
(JA) GM3促進炎症抑制剤及び炎症性サイトカイン産生抑制剤
Abstract:
(EN) The GM3-promoted inflammation inhibitor according to the present invention is characterized by containing, as an active ingredient, a substance that inhibits inflammation promoted by GM3. The substance inhibiting inflammation promoted by GM3 is preferably a ganglioside having two or more sialic acid groups. The ganglioside having two or more sialic acid groups is preferably at least one kind of ganglioside selected from the group consisting of GD1c, GD1a, GT1a, GD3, GD2, GD1b, GT1b, GQ1b, GT3, GT2, GT1c, GQ1c and GP1c. The substance inhibiting inflammation promoted by GM3 preferably has a structure represented by formula (1) [in formula (1): R1 represents a sugar chain constituting ganglioside GM3; and R2-C(=O)- represents a fatty acid residue having not more than 18 carbon atoms or an unsaturated fatty acid residue having 20 or more carbon atoms].
(FR) Un inhibiteur d'inflammation stimulée par GM3 selon la présente invention est caractérisé en ce qu'il contient, en tant que substance active, une substance qui inhibe l'inflammation stimulée par GM3. La substance inhibant l'inflammation stimulée par GM3 est de préférence un ganglioside comportant deux ou plus de deux groupes acide sialique. Le ganglioside comportant deux ou plus de deux groupes acide sialique est, de préférence, au moins un type de ganglioside choisi dans le groupe constitué de GD1c, GD1a, GT1a, GD3, GD2, GD1b, GT1b, GQ1b, GT3, GT2, GT1c, GQ1c et GP1c. La substance inhibant l'inflammation stimulée par GM3 présente de préférence une structure représentée par la formule (1) [dans la formule (1) : R1 représente une chaîne de sucre constituant le ganglioside GM3; et R2-C (=O)- représente un résidu d'acide gras n'ayant pas plus de 18 atomes de carbone ou un résidu d'acide gras insaturé ayant 20 atomes de carbone ou plus].
(JA) 本発明のGM3促進炎症抑制剤は、GM3により促進された炎症を抑制する物質を有効成分として含有することを特徴とする。上記GM3により促進された炎症を抑制する物質は、シアル酸を2個以上有するガングリオシドであることが好ましい。上記シアル酸を2個以上有するガングリオシドは、GD1c、GD1a、GT1a、GD3、GD2、GD1b、GT1b、GQ1b、GT3、GT2、GT1c、GQ1c及びGP1cよりなる群から選ばれる少なくとも1種のガングリオシドであることが好ましい。また、上記GM3により促進された炎症を抑制する物質は、下記式(1)で表される構造を有することが好ましい。[式(1)中、RがガングリオシドGM3を構成する糖鎖を示し、R-C(=O)-が、炭素数18以下の脂肪酸残基、又は炭素数20以上の不飽和脂肪酸残基を示す。]
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)
Also published as:
EP3384928US20180353535